Jacki Jenuth
Private Equity Investor at Lumira Capital Investment Management, Inc.
Profile
Jacki Jenuth is currently a Partner and COO at Lumira Capital Investment Management, Inc. Prior to this, Jacki held positions as Chairman at Kalgene Pharmaceuticals, Inc., Manager at Open Text Corp., Principal at Open Text, Inc., and Principal at Base4 Innovation Ltd.
Jacki's education includes a graduate degree from McGill University and undergraduate and doctorate degrees from the University of Calgary.
Jacki Jenuth active positions
| Companies | Position | Start |
|---|---|---|
Lumira Capital Investment Management, Inc.
 Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | Private Equity Investor | 2011-01-05 |
Former positions of Jacki Jenuth
| Companies | Position | End |
|---|---|---|
Kalgene Pharmaceuticals, Inc.
 Kalgene Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Kalgene Pharmaceuticals, Inc. develops and focuses on personalized cancer diagnostics and drugs. It offers drugs for epithelial and thyroid cancers. The firm's oncology programs are aimed at improving clinical and survival outcomes through the use of personalized medicine, with a particular focus on bladder, epithelial and thyroid cancers. It serves the biopharmaceutical, research and development and health industries. The company is headquartered in Kingston, Canada. | Chairman | - |
Base4 Innovation Ltd.
 Base4 Innovation Ltd. Medical SpecialtiesHealth Technology Base4 Innovation Ltd. develops single molecule detection platforms for healthcare and life sciences. The firm develops DNA sequencing using techniques based on silicon chip technology which can easily be scaled up and this high-throughput technology will cut the time and cost of genetic tests, enabling them to be used much more in patient diagnosis and treatment. The company was founded by Cameron Alexander Frayling in 2007 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - |
Open Text, Inc.
 Open Text, Inc. Packaged SoftwareTechnology Services Part of Open Text Corp., Open Text, Inc. develops and sells software. The private company is based in San Mateo, CA. | Corporate Officer/Principal | - |
| OPEN TEXT CORPORATION | Corporate Officer/Principal | - |
Training of Jacki Jenuth
| McGill University | Graduate Degree |
| University of Calgary | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| OPEN TEXT CORPORATION | Technology Services |
| Private companies | 4 |
|---|---|
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | Finance |
Open Text, Inc.
Open Text, Inc. Packaged SoftwareTechnology Services Part of Open Text Corp., Open Text, Inc. develops and sells software. The private company is based in San Mateo, CA. | Technology Services |
Base4 Innovation Ltd.
Base4 Innovation Ltd. Medical SpecialtiesHealth Technology Base4 Innovation Ltd. develops single molecule detection platforms for healthcare and life sciences. The firm develops DNA sequencing using techniques based on silicon chip technology which can easily be scaled up and this high-throughput technology will cut the time and cost of genetic tests, enabling them to be used much more in patient diagnosis and treatment. The company was founded by Cameron Alexander Frayling in 2007 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Kalgene Pharmaceuticals, Inc.
Kalgene Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Kalgene Pharmaceuticals, Inc. develops and focuses on personalized cancer diagnostics and drugs. It offers drugs for epithelial and thyroid cancers. The firm's oncology programs are aimed at improving clinical and survival outcomes through the use of personalized medicine, with a particular focus on bladder, epithelial and thyroid cancers. It serves the biopharmaceutical, research and development and health industries. The company is headquartered in Kingston, Canada. | Health Services |
- Stock Market
- Insiders
- Jacki Jenuth